SALT LAKE CITY, UT / ACCESSWIRE / February 6, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on April 3, 2024 to stockholders of record at the close of business on March 15, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.
Contact:
Brian Koopman
(801) 566-1200
| Last Trade: | US$58.25 |
| Daily Change: | 0.01 0.02 |
| Daily Volume: | 9,430 |
| Market Cap: | US$186.400M |
November 04, 2025 October 23, 2025 July 24, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
